The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI

NCT02835534 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

818

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute ST Elevation Myocardial Infarction

Interventions

DRUG: rhTNK-tPA
DRUG: alteplase

Sponsor

CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.

Collaborators

[object Object]
[object Object]